{"version":"1.0","provider_name":"Myanmar Newswire","provider_url":"https:\/\/myanmarnewswire.com","author_name":"admin","author_url":"https:\/\/myanmarnewswire.com\/author\/admin\/","title":"Curative Biotechnology Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study - Myanmar Newswire","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"dCVQO8Ijbe\"><a href=\"https:\/\/myanmarnewswire.com\/curative-biotechnology-announces-completion-of-ind-enabling-reformulated-metformin-hcl-eye-drop-study\/\">Curative Biotechnology Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/myanmarnewswire.com\/curative-biotechnology-announces-completion-of-ind-enabling-reformulated-metformin-hcl-eye-drop-study\/embed\/#?secret=dCVQO8Ijbe\" width=\"600\" height=\"338\" title=\"&#8220;Curative Biotechnology Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study&#8221; &#8212; Myanmar Newswire\" data-secret=\"dCVQO8Ijbe\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"Boca Raton, FL, Jan. 05, 2023 (GLOBE NEWSWIRE) \u2014 Curative Biotechnology Inc. (OTC: CUBT) (\u201cCurative Biotech\u201d or the \u201cCompany\u201d), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that it has successfully completed its Investigational New Drug (IND) enabling Tolerance and Toxicology Study of Metformin HCL Solution by Topical [\u2026]","thumbnail_url":"https:\/\/ci4.googleusercontent.com\/proxy\/LqRkgTbdFDv7Jmyu6VcAWVZfUOm79g5hT3090LUTiEwvWQdfDl2KywDTIuUeTu_GDAGg5ld-OiTOdpWGUusJ4g4iRFSG2hPMbDji8De0QKycxMz7tRwqf6uxj4eVOi-NLnYqP5hmUbnMKydFG7cuSv3qK4m2XLLM1ZvaQMvkQBrxJP3FszFBQzLxZXo2HwYMk8_1j_5Ru3JHSy8M=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/YmU3NDE4MTEtYzFhOS00MTVmLTkzN2ItYjAyZTAwZWEzOGUyLTUwMDA3MDkyNw==\/tiny\/Curative-Biotechnology-Inc-.png"}